192 related articles for article (PubMed ID: 28384261)
1. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
2. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
3. Interventions for American cutaneous and mucocutaneous leishmaniasis.
Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
5. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
8. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
9. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
López L; Robayo M; Vargas M; Vélez ID
Trials; 2012 May; 13():58. PubMed ID: 22594858
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
11. The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Tayyebi M; Darchini-Maragheh E; Layegh P; Kiafar B; Goyonlo VM
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009241. PubMed ID: 33739976
[TBL] [Abstract][Full Text] [Related]
12. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
[TBL] [Abstract][Full Text] [Related]
13. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
15. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
16. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
Shanehsaz SM; Ishkhanian S
Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
[TBL] [Abstract][Full Text] [Related]
17. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
Rahman A; Tahir M; Naveed T; Abdullah M; Qayyum N; Malik DH; Amin B
J Coll Physicians Surg Pak; 2023 Dec; 33(12):1367-1371. PubMed ID: 38062590
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Sampaio RNR; Silva JSFE; Paula CDR; Porto C; Motta JOCD; Pereira LIA; Martins SS; Barroso DH; Freire GSM; Gomes CM
Rev Soc Bras Med Trop; 2019 Mar; 52():e20180292. PubMed ID: 30942258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]